KOGENATE FS POWDER FOR SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ANTIHEMOPHILIC FACTOR (RECOMBINANT)

Beschikbaar vanaf:

BAYER INC

ATC-code:

B02BD02

INN (Algemene Internationale Benaming):

COAGULATION FACTOR VIII

Dosering:

2000UNIT

farmaceutische vorm:

POWDER FOR SOLUTION

Samenstelling:

ANTIHEMOPHILIC FACTOR (RECOMBINANT) 2000UNIT

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

100

Prescription-type:

Schedule D

Therapeutisch gebied:

HEMOSTATICS

Product samenvatting:

Active ingredient group (AIG) number: 0124180006; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2018-10-01

Productkenmerken

_ _
_KOGENATE FS Product Monograph_
_Page 1 of 31 _
PRODUCT MONOGRAPH
KOGENATE
® FS
Antihemophilic Factor (Recombinant)
_Formulated with Sucrose _
With Vial Adapter
IV Injection, 250, 500, 1000, 2000, 3000 IU/vial
Coagulation Factor
Bayer Inc.
77 Belfield Road
Toronto, Ontario
M9W 1G6
Canada
www.bayer.ca
Date of Revision:
November 15, 2013
SUBMISSION CONTROL NO: 159265 DATE OF APPROVAL: MAY 30, 2014
2013, Bayer Inc.
® KOGENATE, Bayer, and Bayer Cross are registered trademarks of Bayer
AG, used under
license by Bayer Inc.
_ _
_KOGENATE FS Product Monograph_
_Page 2 of 31 _
TABLE OF CONTENTS
PART
I:
HEALTH
PROFESSIONAL
INFORMATION ..........................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
DESCRIPTION
...........................................................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
...........................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................
9
DOSAGE AND ADMINISTRATION
.....................................................................................
10
OVERDOSAGE
........................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 16
STORAGE AND STABILITY
.................................................................................................
17
SPECIA